Fc Engineered Anti-Human PDGFRA Therapeutic Antibody, a CDC-Enhanced Biobetter [Lot: CB20-PZ16] (CAT#: BioBet-C016ZP) Datasheet

PDGFRA

platelet derived growth factor receptor alpha

This gene encodes a cell surface tyrosine kinase receptor for members of the platelet-derived growth factor family. These growth factors are mitogens for cells of mesenchymal origin. The identity of the growth factor bound to a receptor monomer determines whether the functional receptor is a homodimer or a heterodimer, composed of both platelet-derived growth factor receptor alpha and beta polypeptides. Studies suggest that this gene plays a role in organ development, wound healing, and tumor progression. Mutations in this gene have been associated with idiopathic hypereosinophilic syndrome, somatic and familial gastrointestinal stromal tumors, and a variety of other cancers.

Platelet Derived Growth Factor Receptor Alpha; Platelet-Derived Growth Factor Receptor, Alpha Polypeptide; Alpha-Type Platelet-Derived Growth Factor Receptor; Platelet-Derived Growth Factor Receptor 2; CD140 Antigen-Like Family Member A; CD140a Antigen; PDGF-R-Alpha; EC 2.7.10.1; PDGFR-2;

Protein Based Therapies
Monoclonal antibody (mAb)

Whole Human Antibody

Olaratumab is a fully human IgG1 monoclonal antibody that targets platelet-derived growth factor receptor alpha. It was developed by Eli Lilly and was approved in October 2016 (as Lartruvo) as the initial treatment for certain types of soft tissue sarcoma (STS) adults. Studies have shown that combining olaratumab with adriamycin can significantly reduce the proliferation of cancer cells and tumor growth.

Soft Tissue Sarcoma (STS)

IMC-3G3, LY-3012207

PDGFR signaling is a tyrosine kinase-mediated pathway that normally regulates cell growth, chemotaxis, and mesenchymal stem cell differentiation. Olaratumab is a fully human IgG1 monoclonal antibody with antitumor activity and can selectively bind to the outer domain of human platelet-derived growth factor receptor (PDGFR) -α with high affinity. Olaratumab blocks ligand-induced tumor cell proliferation and inhibits receptor autophosphorylation and ligand-induced phosphorylation of downstream signaling molecules protein kinase B (Akt) and mitogen-activated protein kinase 5.

Olaratumab in combination with adriamycin for the treatment of adult patients with advanced or metastatic soft tissue sarcoma (STS) of histological subtype